Healthcare Equipment and Supplies
Company Overview of Solace Therapeutics, Inc.
Solace Therapeutics, Inc., a medical device company, engages in the development of non-surgical office based treatments for common bladder disorders in the United States. It develops products for various bladder disorders, such as stress urinary incontinence, overactive bladder, male voiding dysfunction, and lower urinary tract symptoms. The company was incorporated in 2002 and is based in Newton, Massachusetts.
135 Newbury Street
Framingham, MA 01701
Founded in 2002
Key Executives for Solace Therapeutics, Inc.
Chief Executive Officer and President
Vice President of Marketing
Compensation as of Fiscal Year 2014.
Solace Therapeutics, Inc. Key Developments
Solace Therapeutics Announces Enrollment of First Patient in the Stress Urinary Incontinence Control Efficacy and Safety Study Pivotal Trial
Sep 4 14
Solace Therapeutics, Inc. announced the company has begun patient enrollment in the SUCCESS Clinical Trial (Stress Urinary InContinence Control Efficacy and Safety Study). The first patient was enrolled by Jeffrey A. Snyder M.D., with Genitourinary Surgical Consultants in Denver, Colorado to Assess Safety and Effectiveness of the Solace Bladder Control Balloon System(TM) for the treatment of Stress Urinary Incontinence (SUI) in Women.
Solace Therapeutics Announces Data from Multicenter 166 Patient Randomized Controlled Study
Nov 14 13
Solace Therapeutics, Inc. announced that data from a multicenter 166 patient randomized controlled study has been published in the December issue of the Journal of Urology. The study demonstrates the safety and effectiveness of limiting rapid pressure changes within the bladder to reduce symptoms of Stress Urinary Incontinence (SUI). Composite end point results (pad weight reduction and quality of life improvement) from this trial showed statistically significant benefit when compared to a sham therapy. The percentage of patients in this study with a greater than 50% decrease in incontinence episode frequency (65.5% treatment vs. 31.3% control) compared favorably to reported results for Botox for overactive bladder (57.5% treatment vs. 28.9% control). Women with SUI typically experience transient increases in intravesical pressure during physical movement including coughing, laughing, sneezing, or during exercise. When this increased bladder pressure exceeds the ability of the urethra to withstand pressure, leakage occurs. Unlike currently available SUI treatments that focus on improving the urethral closure forces, Solace reduces bladder pressure increases with the placement of a compressible air-filled balloon in the bladder. The balloon acts like a "shock-absorber" to prevent rapid changes in pressure and reduce leakage. The un-inflated balloon is placed into the bladder through the urethra and filled in an office procedure without the need for anesthesia. When necessary, the balloon is deflated and removed in a similar office procedure.
Solace Therapeutics Appoints Stacy Enxing Seng as Board of Directors
Sep 17 13
Solace Therapeutics announced that Stacy Enxing Seng has joined the Board of Directors. She serves on the board alongside Ryan Drant, General Partner with New Enterprise Associates (NEA); Ali Behbahani MD, Principal at NEA; John McDonough, CEO at T2 Biosystems; and Kevin G. Connors, founding partner of Spray Venture Partners. Enxing Seng is President of Covidien's Vascular Therapies Global Business Unit.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|